Mounjaro maker wants NHS drug price rises in return for more investment in UK US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministers

#Mounjaro #NHSdrugpricerises #EliLilly #rebatescheme #Mounjaro #weightlossdrug #NHSdrugprices #NHSrebatescheme #antiobesitydrugs #NHScosteffectivenessthresholds #internationaldrugpricing #USUKdrugpricingdeal #brandedmedicines #obesity #obesitytreatment
zurl.co/6jNlv

US pharma MFN and tariff dynamics: What EU and UK leaders need to know Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.

#MostFavouredNationpricing #MFNpricing #MFNpolicy #USpharma #Drugpricing #MFN #Tariffs #accessframeworks #brandedmedicines #MFNframework #MFNthresholds #MFNcalculations #generics #APIs #pharmasupplychains #tariffadvantagedpathways #USUKEconomicProsperityDeal #MFNagreements
zurl.co/OcqZ6

Time to emphasise the economics in health economics Victoria Jordan, ABPI Value and Access Policy Director, discusses the Health Economics of the UK-US Economic Prosperity Deal and the commitment to increase NICE's baseline threshold use, the first cha...

#ABPI #NICE #UKUSEconomicProsperityDeal #innovativemedicines #populationhealth #pharmaceuticalindustry #VPAG #StatutorySchemerebates #priceofmedicines #NHSindustrypartnerships #GVA #RandD #UKResearchandInnovation #clinicaltrials #UKmedicineexports #brandedmedicines #NICEthreshold
zurl.co/D8SUt

Following its deal with the US, the British government has cut the payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access.

healthcaretoday.com/article/gove...

#Healthcare #BrandedMedicines #VPAG #Government #UK #US

Third extension to VPAG granted The deadline for companies to give notice on their intention to leave the voluntary scheme for branded medicines pricing, access, and growth is now 16 December.

The deadline for companies to give notice on their intention to leave the voluntary scheme for branded medicines pricing, access, and growth is now 16 December.

healthcaretoday.com/article/thir...

#healthcare #publichealth #VPAG #brandedmedicines

Pharma says UK is 'tumbling down' rankings for investment The UK is losing out to competitors in attracting investment in R&D, clinical trials, and capital projects, says a report from the ABPI pharma group.

#pharmaceuticals #Pharmainvestment #RandD #clinicaltrials #capitalprojects #innovativenewmedicines #pharmaindustry #ABPI #VPAG #brandedmedicines #pharmaceuticalcompanies #healthcarespending #biotech #pharmaceuticalinnovation #lifesciencespowerhouse #AI #cellandgenetherapies
zurl.co/aDLED

Government and APBI fail to reach agreement on cost of branded medicines The government and pharmaceutical industry representatives have been unable to reach an agreement on NHS branded medicines pricing, the Association of British Pharmaceutical Industry (APBI) has…

The government and pharmaceutical industry representatives have been unable to reach an agreement on NHS branded medicines pricing, the Association of British Pharmaceutical Industry has announced
#ukpharmacy #brandedmedicines

UK doubles statutory payment rate on pharmaceutical sales from July The UK government has doubled the rate that pharmaceutical companies must repay on the sales of newer products to the NHS under the statutory scheme for branded medicines in the second half of 2025, t...

#ABPI #spendingreview #StatutoryScheme #VoluntaryScheme #VPAG #pharmaceuticalsales #UKgovernment #pharmaceuticalcompanies #NHS #brandedmedicines #NHSsales #healthcarebudget #healthcarespending #pharmaindustryinvestment #UK #VPAGreview #lifescienceinvestments
www.abpi.org.uk/media/news/2...

VPAG review brought forward Pressure from the Association of the British Pharmaceutical Industry has brought forward the review of the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth to June.

Pressure from The Association of the British Pharmaceutical Industry (ABPI) has brought forward the review of the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth to June.

healthcaretoday.com/article/vpag...

#healthcare #phamaceuticals #brandedmedicines

ABPI continues attacks on VPAG The Association of the British Pharmaceutical Industry believes that the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), is undermining government efforts to make life scienc...

The ABPI believes that the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), is undermining government efforts to make life sciences a pillar of its industrial strategy.

healthcaretoday.com/article/abpi...

#healthcare #government #brandedmedicines #lifesciences

Pharmacy industry says levy makes Britain uninvestable The ABPI has rallied industry leaders to continue its attack against the government’s increased levy on sales of branded medicines to the NHS.

The ABPI is continuing to attack government plans to fix a scheme which requires companies to record payments up to a quarter to a third of a company’s revenue from sales of branded medicines to the NHS.

healthcaretoday.com/article/phar...

#healthcare #nhs #pharma #brandedmedicines #government

Research into rare diseases hampered by VPAG The rise in the Voluntary Scheme for Branded Medicines Pricing means that NHS patients with rare conditions are missing out on the latest innovations, says ABPI.

The rise in the Voluntary Scheme for Branded Medicines Pricing means that NHS patients with rare conditions are missing out on the latest innovations, according to a survey by the ABPI.

healthcaretoday.com/article/rese...

#publichealth #brandedmedicines #innovation #pharmaceuticals #patientsafety